In Natural Alternatives International, Inc. v. Creative Compounds, LLC., Appeal No. 2018-1295, a divided panel of the Federal Circuit reversed and remanded a decision by the District Court for the Southern District of...more
4/1/2019
/ Appeals ,
Claim Construction ,
Judgment on the Pleadings ,
Method Claims ,
Patent Litigation ,
Patent-Eligible Subject Matter ,
Patents ,
Product of Nature Doctrine ,
Remand ,
Reversal ,
Section 101
On January 12, 2017, the U.S. Court of Appeals for the Federal Circuit issued an opinion affirming the judgement that Eli Lilly’s U.S. Patent No. 7,772,209 (“the ’209 Patent”) was valid and infringed under the doctrine of...more
On September 20, 2016, the U.S. Court of Appeals for the Federal Circuit issued an opinion affirming the summary judgement that Abbott’s U.S. Patent No. 5,344,915 (“the ’915 Patent”) was sufficiently supported by the written...more
10/10/2016
/ Anticipation ,
Appeals ,
Board of Patent Appeals ,
Inherent Disclosure Doctrine ,
Patent Applications ,
Patent Litigation ,
Patents ,
Prior Art ,
Priority Date Cutoff ,
Priority Patent Claims ,
Remand ,
Summary Judgment ,
Written Descriptions